On the contrary, adjunctive use of NOS inhibition in the setting of CS, based on the theory of overproduction of NO by activated iNOS secondary to systemic inflammatory response (Hochman, 2003), was enthusiastic once again in small single-center trials (Cotter et al., 2000, 2003) with L-NMMA (NG-monomethyl L-arginine), a competitive non-specific NOS inhibitor. Here, NOS2 is linked to Cowden syndrome 1.